

Arnaud Scherpereel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6035812/publications.pdf>

Version: 2024-02-01

66
papers

6,025
citations

159573

30
h-index

123420

61
g-index

70
all docs

70
docs citations

70
times ranked

5185
citing authors

#	ARTICLE	IF	CITATIONS
1	First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 198-211.	10.7	773
2	Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. <i>Lancet</i> , The, 2016, 387, 1405-1414.	13.7	753
3	First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet</i> , The, 2021, 397, 375-386.	13.7	638
4	Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. <i>Lancet Oncology</i> , The, 2017, 18, 1261-1273.	10.7	356
5	Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 239-253.	10.7	342
6	Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). <i>Journal of Clinical Oncology</i> , 2021, 39, 619-630.	1.6	317
7	Intestinal <i>Akkermansia muciniphila</i> predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. <i>Nature Medicine</i> , 2022, 28, 315-324.	30.7	225
8	Soluble Mesothelin-related Peptides in the Diagnosis of Malignant Pleural Mesothelioma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 173, 1155-1160.	5.6	218
9	Utility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment. <i>Clinical Cancer Research</i> , 2007, 13, 2928-2935.	7.0	211
10	Serum Mesothelin for Diagnosing Malignant Pleural Mesothelioma: An Individual Patient Data Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2012, 30, 1541-1549.	1.6	199
11	ERS/EACTS statement on the management of malignant pleural effusions. <i>European Respiratory Journal</i> , 2018, 52, 1800349.	6.7	179
12	ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. <i>European Respiratory Journal</i> , 2020, 55, 1900953.	6.7	151
13	Deep Learning on Chest X-ray Images to Detect and Evaluate Pneumonia Cases at the Era of COVID-19. <i>Journal of Medical Systems</i> , 2021, 45, 75.	3.6	132
14	Novel therapies for malignant pleural mesothelioma. <i>Lancet Oncology</i> , The, 2018, 19, e161-e172.	10.7	121
15	Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naïve patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet Respiratory Medicine</i> , the, 2019, 7, 569-580.	10.7	117
16	EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach. <i>Journal of Thoracic Oncology</i> , 2020, 15, 29-49.	1.1	106
17	Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases. <i>Lung Cancer</i> , 2018, 116, 62-66.	2.0	94
18	Scientific Advances and New Frontiers in Mesothelioma Therapeutics. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1269-1283.	1.1	87

#	ARTICLE	IF	CITATIONS
19	Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMANDÂ€” A Double-Blind, Randomized, Phase II Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 790-798.	1.6	79
20	Immunotherapy in Malignant Pleural Mesothelioma. <i>Frontiers in Oncology</i> , 2020, 10, 187.	2.8	66
21	Accuracy of pleural biopsy using thoracoscopy for the diagnosis of histologic subtype in patients with malignant pleural mesothelioma. <i>Cancer</i> , 2007, 110, 2248-2252.	4.1	65
22	Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions. <i>EBioMedicine</i> , 2019, 48, 191-202.	6.1	55
23	ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. <i>European Journal of Cardio-thoracic Surgery</i> , 2020, 58, 1-24.	1.4	50
24	Prevention of Cisplatin-Induced Acute Kidney Injury: A Systematic Review and Meta-Analysis. <i>Drugs</i> , 2019, 79, 1567-1582.	10.9	49
25	Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort. <i>Clinical Lung Cancer</i> , 2019, 20, e564-e575.	2.6	49
26	EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2022, 23, 758-767.	10.7	49
27	Use of Immune Checkpoint Inhibitors in Mesothelioma. <i>Current Treatment Options in Oncology</i> , 2019, 20, 18.	3.0	46
28	Defect in recruiting effector memory CD8+T-cells in malignant pleural effusions compared to normal pleural fluid. <i>BMC Cancer</i> , 2013, 13, 324.	2.6	37
29	Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, LBA8507-LBA8507.	1.6	36
30	Survival inequalities in patients with lung cancer in France: A nationwide cohort study (the) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 302 To	2.5	36
31	Epidemiological Observations on the Association Between Anosmia and COVID-19 Infection: Analysis of Data From a Self-Assessment Web Application. <i>Journal of Medical Internet Research</i> , 2020, 22, e19855.	4.3	33
32	Multi-site tumor sampling highlights molecular intra-tumor heterogeneity in malignant pleural mesothelioma. <i>Genome Medicine</i> , 2021, 13, 113.	8.2	31
33	Tremelimumab as second- or third-line treatment of unresectable malignant mesothelioma (MM): Results from the global, double-blind, placebo-controlled DETERMINE study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8502-8502.	1.6	26
34	Real-life feasibility of home-based pulmonary rehabilitation in chemotherapy-treated patients with thoracic cancers: a pilot study. <i>BMC Cancer</i> , 2018, 18, 178.	2.6	25
35	Bevacizumab 15mg/kg plus cisplatin-pemetrexed (CP) triplet versus CP doublet in Malignant Pleural Mesothelioma (MPM): Results of the IFCT-GFPC-0701 MAPS randomized phase 3 trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 7500-7500.	1.6	22
36	Inequalities in lung cancer: a world of<i>EGFR</i>. <i>European Respiratory Journal</i> , 2016, 47, 1502-1509.	6.7	21

#	ARTICLE	IF	CITATIONS
37	Claudin 3, 4, and 15 expression in solid tumors of lung adenocarcinoma versus malignant pleural mesothelioma. <i>Annals of Diagnostic Pathology</i> , 2015, 19, 193-197.	1.3	19
38	MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial. <i>British Journal of Cancer</i> , 2019, 120, 387-397.	6.4	19
39	Role of Immunotherapy in Small Cell Lung Cancer, Thymic Epithelial Tumors, and Mesothelioma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 543-552.	3.8	17
40	Determinants of malignant pleural mesothelioma survival and burden of disease in France: a national cohort analysis. <i>Cancer Medicine</i> , 2018, 7, 1102-1109.	2.8	15
41	Intrapleural Photodynamic Therapy for Mesothelioma: What Place and Which Future?. <i>Annals of Thoracic Surgery</i> , 2015, 99, 2237-2245.	1.3	14
42	PD-L1 Testing for Immune Checkpoint Inhibitors in Mesothelioma: For Want of Anything Better?. <i>Journal of Thoracic Oncology</i> , 2017, 12, 778-781.	1.1	14
43	National early warning score to predict intensive care unit transfer and mortality in COVID-19 in a French cohort. <i>International Journal of Clinical Practice</i> , 2021, 75, e14121.	1.7	14
44	Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial. <i>Clinical Cancer Research</i> , 2019, 25, 5759-5765.	7.0	13
45	Analysis of clinical pharmacist interventions in the COVID-19 units of a French university hospital. <i>European Journal of Hospital Pharmacy</i> , 2022, 29, e30-e35.	1.1	12
46	Malignant pleural mesothelioma: new treatments, new hopes?. <i>European Respiratory Journal</i> , 2017, 49, 1700319.	6.7	10
47	Achieving Thoracic Oncology data collection in Europe: a precursor study in 35 Countries. <i>BMC Cancer</i> , 2018, 18, 1144.	2.6	9
48	First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743. <i>Lung Cancer</i> , 2022, 167, 8-16.	2.0	9
49	ERS statement on harmonised standards for lung cancer registration and lung cancer services in Europe. <i>European Respiratory Journal</i> , 2018, 52, 1800610.	6.7	8
50	Brain-derived neurotrophic factor, a new soluble biomarker for malignant pleural mesothelioma involved in angiogenesis. <i>Molecular Cancer</i> , 2018, 17, 148.	19.2	8
51	Immune-Checkpoint Inhibitors for Malignant Pleural Mesothelioma: A French, Multicenter, Retrospective Real-World Study. <i>Cancers</i> , 2022, 14, 1498.	3.7	8
52	Stereotactic irradiation of non-small cell lung cancer brain metastases: evaluation of local and cerebral control in a large series. <i>Scientific Reports</i> , 2020, 10, 11201.	3.3	7
53	Immunotherapy in relapsed mesothelioma. <i>Immunotherapy</i> , 2018, 10, 77-80.	2.0	5
54	Real-time light dosimetry for intra-cavity photodynamic therapy: Application for pleural mesothelioma treatment. <i>Photodiagnosis and Photodynamic Therapy</i> , 2017, 18, 155-161.	2.6	4

#	ARTICLE	IF	CITATIONS
55	VAC chemotherapy with valproic acid for refractory/relapsing small cell lung cancer: a phase II study. ERJ Open Research, 2015, 1, 00029-2015.	2.6	2
56	Heterogeneity of treatment effects in malignant pleural mesothelioma – Authors' reply. Lancet, The, 2021, 398, 302.	13.7	2
57	Randomized, double-blind, placebo-controlled study of tremelimumab for second- and third-line treatment of unresectable pleural or peritoneal mesothelioma.. Journal of Clinical Oncology, 2014, 32, TPS7609-TPS7609.	1.6	2
58	Pleural and chest wall tumours. , 2019, , 506-513.		2
59	Reply to K. Masuda et al. Journal of Clinical Oncology, 2019, 37, 2294-2295.	1.6	1
60	Mesothelioma: is chemotherapy alone a thing of the past?. , 2020, , 232-249.		1
61	A defect of amphiregulin release predicted longer survival independently of <sc>YAP</sc> expression in patients with pleural mesothelioma in the <sc>IFCT</sc> – 0701 <sc>MAPS</sc> phase 3 trial. International Journal of Cancer, 2022, 150, 1889-1904.	5.1	1
62	HDAC Inhibition with Valproate Improves Direct Cytotoxicity of Monocytes against Mesothelioma Tumor Cells. Cancers, 2022, 14, 2164.	3.7	1
63	Chemotherapy for Malignant Pleural Mesothelioma: Past, Present and Future. Current Pulmonology Reports, 2017, 6, 155-159.	1.3	0
64	Malignant Pleural Mesothelioma. , 2022, , 510-514.		0
65	Phase I dose-escalation study of an oral administration of the pan-histone deacetylase inhibitor abexinostat combined with a fixed dose of doxorubicin in patients with solid tumors.. Journal of Clinical Oncology, 2014, 32, 2575-2575.	1.6	0
66	Targeting Angiogenesis in Malignant Pleural Mesothelioma. , 2019, , 235-242.		0